ReviewInternational journal of nanomedicine2026
Platelet Lysate-Based Biomaterials for Regenerative Tissue Engineering: A Comprehensive Review.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet lysate (PL), enriched with growth factors, cytokines, and proteins, exhibits strong regenerative potential, positioning it as a promising bioactive agent in tissue engineering (TE). This review systematically summarizes the research progress, applications, and mechanisms of PL-loaded biomaterials in TE. PL-integrated carriers, including hydrogels, scaffolds, and nanoparticles, transform labile liquid PL into stable, tunable platforms that retain its capacities to promote cell proliferation, angiogenesis, immunomodulation, and tissue repair, while enabling spatiotemporal control of efficacy. These composites have demonstrated significant outcomes in wound healing, bone and cartilage repair, neural regeneration, and ocular disease treatment. Critical limitations are addressed, including unstandardized PL preparation, potential immune and metabolic risks, short half-life of active factors, and slow clinical translation. Proposed solutions encompass unified production guidelines, optimized carrier-based sustained-release systems, and large-scale clinical trials. Future research should prioritize interdisciplinary collaboration to enhance precision and translatability, establishing PL-based systems as core modular platforms in regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.